In tablet formulation development for a poorly water-soluble weak base, SBE-β-CD sodium supplied as the Binzhou Zhiyuan pharma-grade API is first dissolved in purified water to form the granulating fluid. Phase-solubility screening by the Higuchi-Connors method is performed with drug concentrations determined by stability-indicating HPLC in pH 1.2, pH 4.5, and pH 6.8 buffers. If the free base has an intrinsic aqueous solubility below 0.01 mg/mL, the isotherm frequently shifts from A_P-type to A_L-type as the SBE-β-CD molar ratio is increased from 1:1 to 5:1. The granulating fluid is sprayed onto a pre-blend of microcrystalline cellulose, lactose monohydrate, and crospovidone in a high-shear granulator. Impeller tip speed is maintained below 6 m/s, and chopper speed is set between 1000 rpm and 1500 rpm. Endpoint is controlled by impeller power consumption or wet mass density, not by fixed granulation time. After drying in a fluid bed at inlet 60–70 °C to a loss-on-drying value below 2.0% w/w, the granules are milled through a 0.8 mm screen and lubricated with sodium stearyl fumarate at 0.5–1.0% w/w. Compression on a rotary tablet press at main compression force 10–20 kN produces tablets with tensile strength above 1.2 MPa and friability below 0.8% when tested according to USP 1216. The dissolution profile is measured in USP 711 Apparatus II at 37 °C and 50 rpm in 900 mL of pH 1.2 or pH 4.5 medium. Under these conditions, the SBE-β-CD granulation reduces delayed release caused by gel formation on the tablet surface; the time to 80% release is compared with a physical mixture control, and the observed difference is recorded without extrapolation. Because SBE-β-CD is hygroscopic above 60% RH, the milled granulation is compressed within 8 h when the suite exceeds 55% RH to avoid picking and sticking. No organic co-solvent is required in the granulating fluid, which simplifies solvent recovery and respiratory protection on the manufacturing line.

What Capsule Fill Weight Fluctuations Reveal About Spray-Dried SBE-β-CD Dispersions

Spray drying of an SBE-β-CD inclusion complex from an aqueous or water-ethanol feed produces an amorphous powder with low bulk density, often in the range 0.25–0.45 g/cm³. A pilot-scale spray dryer with a two-fluid nozzle is operated at inlet temperature 130–170 °C, outlet temperature 65–85 °C, and atomization pressure 1.0–2.0 bar. The recovered powder exhibits a Carr index above 25 and a Hausner ratio above 1.25, indicating poor to very poor flow. On an automatic capsule filling machine using a dosator or tamping pin, fill weight variation on size 0 or size 1 hard gelatin capsules increases when the powder is transferred directly from a dryer. Milling the spray-dried complex through a 0.5 mm screen and blending with silicified microcrystalline cellulose in a 1:1 ratio reduces the fill weight RSD below 3.0%. The powder is not lubricated with magnesium stearate at levels above 1.0% w/w because hydrophobic lubricant reduces wetting and delays dissolution. Crospovidone is incorporated at 2–5% w/w to prevent capsule plug ejection after shell rupture. Dissolution testing uses USP 711 Apparatus II at 75 rpm in 900 mL of pH 1.2 and pH 4.5 media. If the spray-dried complex is stored above 60% RH, moisture uptake causes particle agglomeration and capsule shell brittleness; the blend is therefore filled in an environment below 40% RH. The capsule fill weight is calculated from the molar ratio required to achieve a target solubility multiple, and the final capsule weight is adjusted by inert filler rather than by increasing SBE-β-CD above the phase-solubility plateau. Published data for spray-dried SBE-β-CD complexes vary with API logP and pKa, so a formulation-specific molar ratio is confirmed by microcalorimetry or phase-solubility analysis before scale-up.

Lyophilized Injectable Matrix Collapse and T_g′ Thresholds

A marketed voriconazole lyophilizate contains 200 mg voriconazole and 3200 mg SBE-β-CD per vial, representing an SBE-β-CD-to-drug mass ratio of 16:1. After reconstitution to 10 mg/mL voriconazole, the SBE-β-CD concentration is 160 mg/mL. In lyophilization development, the bulk solution containing SBE-β-CD is filled into type I glass vials and partially stoppered. Freeze-dry microscopy is used to determine the collapse temperature of the specific formulation, because the T_g′ of SBE-β-CD-containing solutions is dependent on total solids, buffer species, and drug concentration. Annealing is conducted at −20 °C for 2 h after an initial freezing ramp to −40 °C. Primary drying is performed at shelf temperature between −20 °C and −10 °C with chamber pressure 100–200 mTorr. Pirani versus capacitance manometer readings are monitored to detect the end of primary drying. Secondary drying at shelf temperature 25–40 °C continues until residual moisture by Karl Fischer is below 1.0% w/w. The resulting cake is inspected for collapse, shrinkage, or meltback. A collapsed cake not only fails appearance specifications but also shows longer reconstitution time and increased turbidity. Reconstitution time is measured by adding sterile water for injection and recording the time to full dissolution with gentle swirling. The injectable solution is then tested for particulate matter per USP 788, sterility per USP 71, and bacterial endotoxins per USP 85. Because SBE-β-CD solutions are viscous at high concentration, the reconstitution protocol should use a 20 mL diluent volume for the concentrated lyophilizate to avoid foaming. If the product is diluted into an infusion bag, the final SBE-β-CD concentration should remain below the level at which the solution becomes highly viscous and difficult to filter.

When SBE-β-CD Replaces Organic Co-Solvents in an Intravenous Admixture

For poorly water-soluble injectable drugs, an SBE-β-CD-containing concentrate can be diluted into 0.9% w/v sodium chloride or 5% w/v dextrose to yield a solution without propylene glycol or ethanol. A US-approved voriconazole concentrate is reconstituted with 19 mL sterile water for injection and diluted to drug concentrations of 0.5–5 mg/mL, producing SBE-β-CD concentrations between 8 mg/mL and 80 mg/mL. The final admixture is not treated as a simple electrolyte solution; the presence of SBE-β-CD can alter the apparent distribution volume of the drug and may compete with other hydrophobic substances. If a second drug is co-administered in the same line, complexation equilibrium can shift when the second drug has a higher cavity affinity, causing measurable precipitation or loss of potency. Compatibility studies with flush solutions, in-line filters, and container materials are therefore performed with the complete admixture at the intended final concentration. Polyolefin infusion bags are preferred when the active substance is highly lipophilic, because the inclusion complex reduces but does not eliminate sorption to PVC. The admixture is used within the time specified by the stability study; published data for this specific configuration is limited beyond the approved product labels. Filtration of the diluted admixture through a 0.2 μm in-line filter is possible if the final SBE-β-CD concentration is below the viscosity limit of the filter membrane. Infusion rate is controlled by the drug product label; SBE-β-CD itself does not determine the infusion rate but contributes to the osmotic load, so osmolality is measured by freezing point depression according to USP 785. The replacement of organic co-solvents reduces the risk of solvent-induced pain and hemolysis associated with propylene glycol, but the anionic cyclodextrin introduces its own incompatibility with cationic drugs and with preservatives such as benzalkonium chloride, which can displace the active ingredient from the cavity.

Oral granules for reconstitution or direct administration use SBE-β-CD to mask bitterness and improve dissolution of a drug that is otherwise poorly water-soluble. A fluid bed top-spray process runs with bed temperature 35–45 °C and atomization air pressure 1.5–2.5 bar. The binder solution is prepared by dissolving SBE-β-CD at 10–30% w/w in purified water, optionally with a film-forming polymer such as hypromellose at 2–5% w/w. The dry substrate is a sugar-free core of mannitol or isomalt with particle size 100–300 μm. Spraying continues until the target SBE-β-CD-to-drug molar ratio is reached, and the granules are dried to moisture below 1.5% w/w. Particle size distribution is checked by analytical sieving per USP 786; fines below 75 μm are kept below 20% w/w to reduce segregation during sachet filling. If the granules are reconstituted into an oral suspension, xanthan gum is added at 0.2–0.5% w/v as a suspending agent, and a preservative is selected that does not compete with the inclusion complex. The reconstituted suspension is stored at 2–8 °C and used within 14 days unless microbial challenge testing supports a longer period. Dissolution of the granules is measured in USP 711 Apparatus II at 37 °C in 500 mL of pH 1.2 and pH 4.5 media with 50 rpm. SBE-β-CD-containing granules are filled into sachets under 25% RH because moisture uptake above 60% RH causes caking and loss of flow. The sachet material is a foil laminate with a desiccant pocket when the bulk granule lacks a moisture barrier. Bitter taste masking is confirmed by electronic tongue or human sensory panel according to the required protocol for the target patient population; this test is not replaced by dissolution data alone.

Why Terminal Sterilization of Ready-to-Use Vials Requires Viscosity-Based Filter Sizing

When SBE-β-CD is used in a ready-to-use injectable solution at concentrations of 20–40% w/v, the dynamic viscosity increases to levels that affect filtration and filling. A stainless steel or glass-lined mixing vessel is used to prepare the bulk solution at 35–45 °C to reduce viscosity before membrane filtration. Filtration is performed through a 0.22 μm polyvinylidene fluoride cartridge or capsule with differential pressure maintained below 15 psi. Filter capacity is estimated by Vmax testing at constant pressure, and the actual batch is filtered within the validated volume per filter cartridge. After aseptic filling, terminal sterilization at 121 °C for 15 min can be applied only when the active pharmaceutical ingredient is thermally stable under the chosen pH and buffer conditions. SBE-β-CD itself is not the limiting factor for terminal sterilization; complex integrity must be confirmed by HPLC after the thermal cycle because elevated temperature can shift the equilibrium toward free drug, causing precipitation in the ampule or vial. The solution is characterized by osmolality per USP 785, pH, and subvisible particulate matter per USP 788. If terminal sterilization is not feasible, aseptic filtration and filling are used, but the same viscosity-based filter sizing applies. Filling lines with ceramic piston pumps require product-specific fill volume adjustments because high-viscosity SBE-β-CD solutions may cavitate at high pump speeds. The final container is type I borosilicate glass with a halogenated butyl rubber stopper; compatibility between the anionic cyclodextrin and the elastomer is evaluated by extractables testing under accelerated conditions. A ready-to-use solution containing SBE-β-CD is not freeze-dried; it is provided as a liquid and must be protected from freezing during shipment because freeze-thaw cycles can disrupt the inclusion complex and produce visible particles.

Intramuscular Reconstituted Powder and Injection-Site Precipitation Limits

For intramuscular administration, SBE-β-CD is used in a reconstituted powder form to increase the aqueous solubility of a poorly water-soluble drug without using organic co-solvents. A US-approved ziprasidone mesylate injection contains 20 mg/mL ziprasidone and 294 mg/mL SBE-β-CD after reconstitution, demonstrating that high excipient-to-drug mass ratios are required when the drug has very low intrinsic solubility. The powder is prepared by lyophilization or by filling a sterile milled solid, and reconstitution uses sterile water for injection to the target volume. Reconstitution time is specified because high local viscosity in the powder mass can prolong wetting and cause foaming. The reconstituted solution is for immediate use, and any residual particulate matter is controlled by the drug product specification. Upon injection into muscle, the SBE-β-CD complex dissociates as the drug partitions into tissue; the rate and completeness of absorption depend on injection volume, tissue perfusion, and the free drug concentration at the injection site. Local precipitation can occur if the dose exceeds the solubilization capacity of the administered SBE-β-CD or if the vehicle is diluted too rapidly by interstitial fluid. The formulation is therefore not diluted with normal saline before injection unless the product label permits it. The pH of the reconstituted solution is controlled to minimize tissue irritation, but the clinical acceptability is established by the approved drug product, not by the excipient alone. Stability after reconstitution is limited, and the product is not stored in plastic syringes beyond the label-defined period because SBE-β-CD can interact with rubber or polycarbonate components. No organic co-solvent is used, which reduces the intramuscular injection pain associated with propylene glycol or benzyl alcohol, but the high osmolality of the SBE-β-CD solution must remain within the limits established by the drug product approval.